TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Merck: FDA reviewing tablet to eliminate allergy

Daily Photo Galleries

By The Associated Press
Thursday, March 28, 2013, 12:01 a.m.
 

Drugmaker Merck & Co. says federal regulators are reviewing its application to sell a new type of treatment for grass pollen allergy that reduces symptoms over time, rather than just temporarily relieving the sneezing and itching.

The treatment, a tablet that dissolves under the tongue, could become the first alternative available in the United States to a long series of uncomfortable allergy shots. Both methods work by gradually desensitizing the patient's immune system to the substance triggering the allergic reaction. Merck's immunotherapy, still unnamed, would be taken daily throughout allergy season.

for three years.

The company, which is based in Whitehouse Station, N.J., also recently applied to the Food and Drug Administration for approval to sell an immunotherapy tablet for ragweed pollen.

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. Hiring in shale industry shifts to engineering, construction workers
  2. State to seek comments on drilling below Loyalsock State Forest
  3. Tech giants lead rush for profits in foreign countries
  4. Consol Energy posts $25 million loss despite gas gains
  5. Hotels, restaurants lead job additions in Pittsburgh region
  6. U.S. Steel’s 2Q loss beats analysts’ estimates
  7. GNC revenue, sales drop, but vitamin retailer says plan in place
  8. Home price gains slow for 6th-straight month
  9. Fed to keep cards close to the vest
  10. China investigates Microsoft in monopoly case
  11. Market in neutral, awaiting economic news
Subscribe today! Click here for our subscription offers.